Difference between revisions of "P53"
Jump to navigation
Jump to search
(+infobox) |
|||
| Line 10: | Line 10: | ||
| Use = cancer versus benign, prognostication | | Use = cancer versus benign, prognostication | ||
| Subspecial = | | Subspecial = | ||
| Pattern = | | Pattern = | ||
| Positive = | | Positive = nuclear staining | ||
| Negative = | | Negative = | ||
| Other = | | Other = | ||
| Line 19: | Line 19: | ||
==See also== | ==See also== | ||
*[[Molecular pathology]]. | *[[Molecular pathology]]. | ||
*[[Li-Fraumeni syndrome]]. | |||
==References== | ==References== | ||
Revision as of 15:22, 19 March 2018
| P53 | |
|---|---|
| Immunostain in short | |
 p53 staining in an anaplastic astrocytoma. | |
| Use | cancer versus benign, prognostication |
| Positive | nuclear staining |
p53 is a tumour suppressor commonly implicated in cancer and common immunostain.